Scholarlink

Background <p>Despite the importance of metabolic reprogramming in prostate cancer initiation and progression, little is known about metabolic features associated with prostate cancer risk among Black Americans.</p> Methods <p>This nested case-control study included 195 incident prostate cancer cases and 379 matched controls, focusing on Black Americans from the Southern Community Cohort Study. Using pre-diagnostic plasma samples, a global, semi-quantitative metabolomics assay was conducted. Multivariable-adjusted conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for prostate cancer risk associated with a one standard-deviation increase in log-transformed metabolite levels.</p> Results <p>A total of 26 metabolites were associated with incident prostate cancer at <i>p</i> &lt; 0.01. Of them, seven metabolites were independently associated with prostate cancer risk after mutual adjustment, including S-adenosylhomocysteine (SAH; OR [95% CI] = 0.69 [0.55–0.88]), 14-HDoHE/17-HDoHE (1.46 [1.17–1.83]), 1-linoleoyl-GPI (18:2)* (0.73 [0.57–0.92]), Sphingomyelin (d17:1/16:0, d18:1/15:0, d16:1/17:0)* (1.28 [1.03–1.59]), Gamma-glutamyl-epsilon-lysine (1.45 [1.14–1.85]), and 2,2’-Methylenebis(6-tert-butyl-p-cresol) (0.62 [0.40–0.95]). SAH and 14-HDoHE/17-HDoHE were exclusively linked to aggressive prostate cancer, while the other five metabolites were primarily associated with non-aggressive forms.</p> Conclusions <p>We found several circulating metabolites as potential biomarkers for prostate cancer risk among Black Americans. Further large-scale studies are warranted to confirm our findings and to elucidate potential mechanisms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Circulating metabolite biomarkers associated with prostate cancer risk in Black Americans: findings from the Southern Community Cohort Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月27日

查看全文
  • Hyung-Suk Yoon,
  • Xiao-Ou Shu,
  • Jie Wu,
  • Maureen Sanderson,
  • Xiaofei Wang,
  • Wanqing Wen,
  • Regina Courtney,
  • Jae Jeong Yang,
  • William J. Blot,
  • Wei Zheng,
  • Qiuyin Cai

摘要

Background

Despite the importance of metabolic reprogramming in prostate cancer initiation and progression, little is known about metabolic features associated with prostate cancer risk among Black Americans.

Methods

This nested case-control study included 195 incident prostate cancer cases and 379 matched controls, focusing on Black Americans from the Southern Community Cohort Study. Using pre-diagnostic plasma samples, a global, semi-quantitative metabolomics assay was conducted. Multivariable-adjusted conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for prostate cancer risk associated with a one standard-deviation increase in log-transformed metabolite levels.

Results

A total of 26 metabolites were associated with incident prostate cancer at p < 0.01. Of them, seven metabolites were independently associated with prostate cancer risk after mutual adjustment, including S-adenosylhomocysteine (SAH; OR [95% CI] = 0.69 [0.55–0.88]), 14-HDoHE/17-HDoHE (1.46 [1.17–1.83]), 1-linoleoyl-GPI (18:2)* (0.73 [0.57–0.92]), Sphingomyelin (d17:1/16:0, d18:1/15:0, d16:1/17:0)* (1.28 [1.03–1.59]), Gamma-glutamyl-epsilon-lysine (1.45 [1.14–1.85]), and 2,2’-Methylenebis(6-tert-butyl-p-cresol) (0.62 [0.40–0.95]). SAH and 14-HDoHE/17-HDoHE were exclusively linked to aggressive prostate cancer, while the other five metabolites were primarily associated with non-aggressive forms.

Conclusions

We found several circulating metabolites as potential biomarkers for prostate cancer risk among Black Americans. Further large-scale studies are warranted to confirm our findings and to elucidate potential mechanisms.